CRELY aims to detect problems early
Catching issues early is sometimes the best form of medicine there is. With enough time, power and resources, catching something early is the difference between life and death. For this medical-device startup out of Oxnard, catching something early is literally in its name. CRELY, a shorthand for credible, reliable, and early, was founded in 2018, Read More →
Inogen sees slight stock climb behind regulatory wins
Goleta-based Inogen saw its stock climb about 3% after the company achieved regulatory milestones in the European Union and the United States to support its products and shared its preliminary fourth quarter and full-year revenue results on Jan. 10. Inogen, a maker of portable oxygen containers, received European Medical Device Regulation certification from the British Read More →
Arcutis approves equity grants
Westlake Village-based Arcutis Biotherapeutics announced the grant of an aggregate of 17,050 restricted stock units of Arcutis’ common stock as well as options to purchase an aggregate of 33,550 shares of Arcutis’ common stock to five newly hired employees. The stock options have a ten-year term and an exercise price of $14.77 per share, equal to Read More →
Community Memorial Health adds CEO, Chief of Staff
Mick Zdeblick officially stepped into his new role as the CEO of Community Memorial Health on Jan. 9, replacing Gary Wilde, who retired after helming the position since 2004. Community Memorial Health, which offers a network of services throughout Ventura County, welcomes Zdeblick from Medford, Oregon, where he served as the CEO of Asante Rogue Read More →
Health Forecast: ‘Tripledemic’ a real concern to start 2023
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Capsida announces multi-year agreement with Eli Lilly subsidiary
Thousand Oaks-based Capsida Therapeutics has entered into a multi-year agreement with Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, to develop transformative genetic medicines for serious diseases, Capisda announced Jan. 4. As per the agreement, Capsida will receive $55 million in the form of an upfront payment and a commitment to participate Read More →
Amgen buys Horizon Therapeutics for $27B
By Jorge Mercado Senior Staff Writer Thousand Oaks-based Amgen has announced its largest acquisition in company history, $27 billion for Horizon Therapeutics, positioning itself with a pipeline of treatments that could pay dividends over the coming decades. Amgen, one of the largest biotechnology companies in the world, beat out competition from Sanofi and Johnson and Read More →
